Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 942

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 5
Chunk 942
---
(259,679)NET CHANGE IN CASH AND CASH EQUIVALENTS  (1,630,744)  2,398,846 CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR  4,517,710   2,118,864          CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR $2,886,966  $4,517,710          CASH AND CASH EQUIVALENTS INFORMATION:        Fixed deposits placed with financial institutions with original maturities of three months or less $1,303,487  $1,893,745 Cash at bank  1,583,479   2,623,965 Cash and cash equivalents, end of financial year  2,886,966   4,517,710          Supplementary cash flow information:        Interest paid $(9,351) $(8,877)Income tax refunded  -   312 Income tax paid  (40,380)  (66,973)

See accompanying notes to the consolidated financial statements.

 F-9Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of BioNexus Gene Lab Sdn. Bhd., incorporated in Malaysia on April 7, 2015 which then subsequently changed its name to MRNA Scientific Sdn. Bhd. (MRNA Scientific) on September 19, 2023. The principal office address is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5 Jalan Bangsar Utama 1, Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at